IGI Laboratories Announces the Submission of Sixth ANDA
June 05 2012 - 8:00AM
Business Wire
IGI Laboratories, Inc. (NYSE Amex: IG), a New Jersey based
formulation and manufacturing company, today announced that it has
submitted an additional abbreviated new drug application (ANDA) to
the US FDA, bringing the company’s total number of submissions to
six.
IGI President and CEO Charlie Moore commented, “Our team has
done a tremendous job in effectively managing our development
projects. We have built a strong development group, and the team
now has six ANDA filings with the US FDA. We expect to file
three-to-five additional ANDAs in 2012, which will bring our total
of ANDA submissions to nine to eleven by the end of 2012.” The
development of ANDA products has successfully been integrated into
the Company’s ongoing contract services business.
About IGI Laboratories, Inc.
IGI Laboratories is focused in the development and
commercialization of products for the dermatology market.
IGI Laboratories, Inc. “Safe Harbor” Statement under the Private
Securities Litigation Reform Act of 1995. This press release
includes certain "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, but are not limited to, plans,
objectives, expectations and intentions, and other statements
contained in this press release that are not historical facts and
statements identified by words such as " will," "possible," "one
time," "provides an opportunity," "continue" or words of similar
meaning. These statements are based on our current beliefs or
expectations and are inherently subject to various risks and
uncertainties, including those set forth under the caption "Risk
Factors" in IGI Laboratories, Inc.’s most recent Annual Report on
Form 10-K and Quarterly Reports on Form 10-Q as filed with the
Securities and Exchange Commission. Actual results may differ
materially from these expectations due to changes in global
political, economic, business, competitive, market and regulatory
factors or IGI Laboratories, Inc.’s ability to implement business
strategies. IGI Laboratories, Inc. does not undertake any
obligation to update any forward-looking statements contained in
this document as a result of new information, future events or
otherwise.
Teligent (NASDAQ:TLGT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Teligent (NASDAQ:TLGT)
Historical Stock Chart
From Apr 2023 to Apr 2024